NO954389L - Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte - Google Patents

Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte

Info

Publication number
NO954389L
NO954389L NO954389A NO954389A NO954389L NO 954389 L NO954389 L NO 954389L NO 954389 A NO954389 A NO 954389A NO 954389 A NO954389 A NO 954389A NO 954389 L NO954389 L NO 954389L
Authority
NO
Norway
Prior art keywords
salt
squalene synthetase
synthetase inhibitor
phosphonosulfonate
inhibitor salts
Prior art date
Application number
NO954389A
Other languages
English (en)
Other versions
NO954389D0 (no
Inventor
Yadagiri Pendri
Chung Pin Chen
David J Kucera
Eduardo J Martinez
Paul D Pansegrau
John K Thottathil
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO954389D0 publication Critical patent/NO954389D0/no
Publication of NO954389L publication Critical patent/NO954389L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Oppfinnelsen tilveiebringer nye saltformer av fosfono- sulfonatsqualen-syntetaseinhibitoren: SO,H'«alt som innbefatter kalsiumsaltet, t-butylaminsaltet, t-oktylamin- saltet og dehydroabietylaminsaltet. Disse saltene hemmer kolesterol biosyntesen og kan derfor brukes for å senke serum- kolesterol og for å behandle atherosklerose.
NO954389A 1994-11-03 1995-11-02 Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte NO954389L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33366194A 1994-11-03 1994-11-03

Publications (2)

Publication Number Publication Date
NO954389D0 NO954389D0 (no) 1995-11-02
NO954389L true NO954389L (no) 1996-05-06

Family

ID=23303735

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954389A NO954389L (no) 1994-11-03 1995-11-02 Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte

Country Status (14)

Country Link
EP (1) EP0710665A1 (no)
JP (1) JPH08208672A (no)
KR (1) KR960017680A (no)
CN (1) CN1130188A (no)
AU (1) AU3458795A (no)
CA (1) CA2159850A1 (no)
CZ (1) CZ279595A3 (no)
FI (1) FI955256A (no)
HU (1) HUT73140A (no)
IL (1) IL115537A0 (no)
NO (1) NO954389L (no)
PL (1) PL311218A1 (no)
TW (1) TW318852B (no)
ZA (1) ZA959326B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US20040063750A1 (en) * 2000-11-09 2004-04-01 Tomoyuki Nishimoto High-density lipoprotein-cholesterol level elevating agent
BRPI0610722A2 (pt) 2005-04-18 2016-11-16 Univ California métodos para tratar uma infecção bacteriana, para prevenir, tratar ou melhorar o tratamento eficaz de mrsa, para inibir o crescimento de um micróbio, e para selecionar um agente terapêutico de mrsa útil pata tratar uma infcção bacteriana, e, composição
CN101460059B (zh) * 2006-05-12 2013-11-06 加利福尼亚大学董事会 用于治疗微生物感染的化合物及其制药用途
CN101580472B (zh) * 2009-06-24 2013-07-10 广西壮族自治区化工研究院 1,1'-联-2-萘酚的拆分剂以及拆分方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2107644A1 (en) * 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors

Also Published As

Publication number Publication date
AU3458795A (en) 1996-05-09
PL311218A1 (en) 1996-05-13
NO954389D0 (no) 1995-11-02
FI955256A (fi) 1996-05-04
FI955256A0 (fi) 1995-11-02
CZ279595A3 (en) 1996-08-14
JPH08208672A (ja) 1996-08-13
EP0710665A1 (en) 1996-05-08
CA2159850A1 (en) 1996-05-04
ZA959326B (en) 1997-05-05
KR960017680A (ko) 1996-06-17
HU9503136D0 (en) 1995-12-28
TW318852B (no) 1997-11-01
CN1130188A (zh) 1996-09-04
IL115537A0 (en) 1996-01-19
HUT73140A (en) 1996-06-28

Similar Documents

Publication Publication Date Title
WO1996040745A3 (en) Amino acid amides of 5-amino-1,3,4-thiadiazones and their use as inhibitors for matrix metalloproteinases
IL111670A0 (en) Isoxazoline compounds as antiinflammatory agents
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
AU6328094A (en) Saccharin derivative proteolytic enzyme inhibitors
BG102738A (en) Inhibitors of farnesyl-protein transferase
ATE114661T1 (de) Benzylphosphonsäure-tyrosinkinaseinhibitoren.
SG52659A1 (en) Saccharin derivative proteolytic enzyme inhibitors
NO972043D0 (no) Tienopyridin eller tienopyrimidinderivater og deres anvendelse
BR0010220A (pt) Compostos de pirimidinona
BR0211551A (pt) Controle de desenvolvimento de biofilmes em água de processo industrial
CA2144372A1 (en) Composition for water treatment
MY112413A (en) Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
MY116539A (en) New amino acid derivatives
HUT44244A (en) Process for preparing isoxazoles inhibiting transglutaminase
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
CA2020858A1 (en) Water treatment agent and water treatment method for boiler
NO975878D0 (no) Framgangsmåte for behandling av avfallslam
NO954389L (no) Fosfonosulfonat-squalensyntetase-inhibitor-salter og fremgangsmåte
MX9704575A (es) Compuestos quimicos.
MA23790A1 (fr) Procede pour desactiver ou detruire des microorganismes
DK0712278T3 (da) N-pyridyltoluidinholdigt svampedræbende, vanddispergerbart granulat
MX9803645A (es) Microparticulas minerales sinteticas, auxiliar de retencion, sistemas de tratamiento de agua y metodos que usan dichas particulas.
BG104292A (en) Methods and compositions for the treatment of rheumatoid arthritis
AU7063287A (en) A composition for inhibiting corrosion in industrial cooling waters and a method for improving the performance of corrosion inhibitors in same
MX9202015A (es) Esteres aril alquilicos de acido 4,5-di hidroxi -9,10- di hidro-9,10-di oxo --2- antracen carboxilico que tienen actividad terapeutica.